CORTIPOL 20 MG I.M./ I.V. POWDER AND SOLVENT FOR PREPARING INJECTION/INFUSION SOLUTIONS

CORTIPOL 20 MG I.M./ I.V. POWDER AND SOLVENT FOR PREPARING INJECTION/INFUSION SOLUTIONS
Product Description

CORTİPOL is indicated to treat any condition in which rapid and intense corticosteroid effect is required such as: Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation): rheumatoid arthritis (including juvenile rheumatoid arthritis with low-dose therapy), psoriatic arthritis, ankylosing spondylitis, acute gouty arthritis, post-traumatic osteoarthritis, acute non-specific tenosynovitis, acute and subacute bursitis and epicondylitis, osteoarthritis synovitis. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis, (polymyositis), acute rheumatic carditis. Dermatologic diseases: pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrhoeic dermatitis, severe psoriasis and mycosis fungoides Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, seasonal or perennial allergic rhinitis, drug hypersensitivity reactions, urticarial transfusion reactions, acute non-infectious laryngeal oedema Eye disorders: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus, iritis, iridocyclitis, chorioretinitis, diffuse posterior uveitis and  choroiditis, optic neuritis, sympathetic ophthalmia, anterior segment inflammation, allergic conjunctivitis, allergic corneal marginal ulcers and keratitis Gastrointestinal disorders: To tide the patient over a critical period of the disease in: ulcerative colitis (systemic therapy) and regional enteritis (systemic therapy)

Polifarma Ilac

  • TR
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Pharmaceutical company
Primary activities
Animal Health
Finished Formulation products Distributor/Buyer
Laboratory, Analytical, Biotechnology Equipment
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Transport/Logistics/Distribution
Specifications
  • CAS Registry Number
    28.06.2021 2021/189
  • Supplied from
    Türkiye

Polifarma Ilac

  • TR
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Pharmaceutical company
Primary activities
Animal Health
Finished Formulation products Distributor/Buyer
Laboratory, Analytical, Biotechnology Equipment
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Transport/Logistics/Distribution

More Products from Polifarma Ilac (54)

Polifarma Ilac resources (1)